Microsoft word - press release english v3.doc
China Grand Pharmaceutical and Healthcare Holdings Limited
(Incorporated in Bermuda with limited liability)
China Grand Pharmaceutical expands her new product pipeline with an eye on the future
Wuhan Grand Pharmaceutical Group Company Limited, a subsidiary of China Grand Pharmaceutical
and Healthcare Holdings Limited, signed agreements on the product development and technology
transfer of four projects with Tianjin Institute of Pharmaceutical Research and Xi’an Xintong Drug
Research Company Limited, respectively. The four projects are: Olprinone injection (a Category 3.1
new drug), Candesartan cilexetil and Hydrochlorothiazide capsules (a Category 3.2 new drug),
Penciclovir injection (a Category 2 new drug) and Amlodipine Besylate and Telmisartan tablets (a
Category 3.2 new drug). Under the terms of the Agreement, these new products are scheduled to be
on the market in 2012 and thereafter. Wuhan Grand Pharmaceutical Group Company Limited will
possess the rights to manufacture and market the above four products in the mainland China.
Under the terms of the agreement, Tianjin Institute of Pharmaceutical Research will be responsible for
clinical research, regular filing, registration, declaration and certification of Candesartan cilexetil and
Hydrochlorothiazide capsules as a state new drug. The capsule is a compound preparation for
hypertension, popular in European and American markets and is now under clinical research as a state
Category 3 new drug in the mainland China.
Under the terms of the agreement, Xi’an Xintong Drug Research Company Limited will be
responsible for clinical research, regular filing, registration, declaration and certification of Olprinone
injection and Penciclovir injection as a state new drug, respectively and for pre-clinical research,
regular filing, declaration and approvals of Amlodipine Besylate and Telmisartan tablets for clinical
study in China. Olprinone injection is a Category 3 new drug, which is a new generation of
phosphodiesterase III inhibitor for the treatment of heart failure. This product is more effective and
safer than similar drugs in the market such as Milrinone and Inamrinone. Penciclovir is a medicine
for severe herpes virus infection, but is only for external use in European and American markets
because of its poor absorption if taken orally. Penciclovir injection (transfusion) is registered and
declared as a Category 2 new drug by changing the route of administration. It will provide a new
medication for severe herpes zoster virus infection. The product has passed Phase-II clinical trials
and it will enter Phase III. Amlodipine Besylate and Telmisartan tablet is now the most unique and
latest compound preparation for hypertension in which the pre- clinical research has been completed,
it will be registered and declared as a Category 3 new drug in China.
Wuhan Grand Pharmaceutical Group Company Limited has been building a full and sustainable new
product pipeline through the internal research and development, and the external project cooperation
and product licensing. The development of Candesartan cilexetil and Hydrochlorothiazide capsules,
Olprinone injection and Telmisartan/ Amlodipine tablet will effectively expand her new product
pipeline in cardiovascular therapeutic area; the development of Penciclovir injection will further
reinforce the Company’s market position in anti-infective therapeutic area.
Wuhan Grand Pharmaceutical Group Company Limited is a well-known mainland China-based
pharmaceutical enterprise. Tianjin Institute of Pharmaceutical Research is a national integrated
pharmaceutical research institute administrated directly under the State Food and Drug Administration.
As a high-tech enterprise mainly engaged in new drug research, it is one of the most powerful and
influential research institutes. Xi’an Xintong Drug Research Company Limited is a high-tech
pharmaceutical research enterprise in Shaanxi Province with a strong research team, advanced
facilities and high productivity. It is mainly engaged in research and development of chemical
medicines and traditional Chinese medicines including pre-clinical studies, clinical studies, regular
filing, product registration as well as technology transfer and consultation.
Research J. Pharm. and Tech. 1(4): Oct.-Dec. 2008, ISSN 0974-3618 www.rjptonline.org RESEARCH ARTICLE Formulation and Evaluation of Sustained Release Matrix Tablet of Anti-Anginal Drug, Influence of Combination of Hydrophobic and Hydrophlic Matrix Former SH Lakade* and MR Bhalekar Sinhgad College of Pharmacy Lonavala Pune-411401, AISSMS college of Pharmacy,
29 de Septiembre 4050/52 - Remedios de Escalada 0810-222-0606 firstname.lastname@example.org Los precios no incluyen IVA ni arancel Senasa Lista de Precios De Artículos Descripción - Accesorios - P191 BOLSO FULL C/VENTIL.ANIMAL PLAN MEDIANO (320)BOLSO FULL C/VENTIL.ANIMAL PLAN.CHICO (319)BOLSO FULL C/VENTIL.CHICO ABERTURA ANT.(301)BOLSO FULL DE LUJO CHICO C/COLCHONETA (303)BOMBACHA